Edwards LifesciencesEW +3.12%97 EBITDA Margin % is 33.70% as of Mar. 2026, which is 12% above its 10-year median of 30.00. GuruFocus rates EW with a GF Score™ of 97/100 and a GF Value™ of $93.14 (Fairly Valued). The stock has 5 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Edwards Lifesciences ranks better than 83.95% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Edwards Lifesciences EBITDA Margin % Related Terms
Edwards Lifesciences EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Edwards Lifesciences's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Edwards Lifesciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Edwards Lifesciences EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Edwards Lifesciences's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Edwards Lifesciences's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edwards Lifesciences (EW) has a EBITDA Margin % of 33.70% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Edwards Lifesciences and its competitors. This is 12% above median its historical median of 30.00. Over the past decade, Edwards Lifesciences' EBITDA Margin % has ranged from 23.33 to 37.60. According to the industry distribution chart, Edwards Lifesciences ranks #131 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 16.1%.
Is Edwards Lifesciences' EBITDA Margin % too high?
Edwards Lifesciences' current EBITDA Margin % of 33.70% is 12% above median its 10-year median of 30.00. Over the past 10 years, this metric has ranged from a low of 23.33 to a high of 37.60. The Medical Devices & Instruments industry median EBITDA Margin % is 7.48. Edwards Lifesciences' value of 33.70% is 350.8% above this industry median. Based on the distribution chart, Edwards Lifesciences ranks #131 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Edwards Lifesciences has a GF Score™ of 97/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Edwards Lifesciences' EBITDA Margin % compare to DXCM and GEHC?
According to the Medical Devices & Instruments industry distribution chart, Edwards Lifesciences ranks #131 out of 816 companies for EBITDA Margin %. This places Edwards Lifesciences in the top 16% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.48. Edwards Lifesciences' value of 33.70% is 350.8% above this benchmark. Historically, Edwards Lifesciences' own EBITDA Margin % has ranged from 23.33 to 37.60 over the past decade. While the company's 10-year median is 30.00 vs. the industry median of 7.48, Edwards Lifesciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Edwards Lifesciences's current EBITDA Margin % of 33.70% is 350.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Edwards Lifesciences and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edwards Lifesciences's current EBITDA Margin % is 33.70%, which is 12% above median its own 10-year median of 30.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edwards Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Edwards Lifesciences (EW) is currently considered Fairly Valued. The stock's GF Value™ is $93.14, compared to a current price of $89.66 — trading 3.7% below its estimated fair value. The current EBITDA Margin % is 33.70%, which is 12% above median its 10-year median of 30.00 and 350.8% above the Medical Devices & Instruments industry median of 7.48. Edwards Lifesciences' overall GF Score™ is 97/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Edwards Lifesciences (EW), the current EBITDA Margin % is 33.70% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Edwards Lifesciences (EW) Overvalued in 2026?
Based on GuruFocus' analysis, Edwards Lifesciences stock appears to be undervalued.
The current stock price of $89.66 is trading 3.7% below its estimated GF Value™ of $93.14.
GuruFocus considers Edwards Lifesciences to be Fairly Valued.
Key valuation signals for EW:
EBITDA Margin %: 33.70% (12% above median its 10-year median of 30.00)
GF Value™: $93.14 vs. price of $89.66 (3.7% below fair value)
Industry Position: 350.8% above the Medical Devices & Instruments median (#131 of 816)
No single metric tells the full story. See the EW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.
97GF Score
Get the complete analysis for EW
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EW has been successfully added to your 
